Board of Directors

Dr. Mates has been the Chairman of the board of directors, President and Chief Executive Officer of ITI since June 2002. Dr. Mates co-founded ITI in May 2002. Prior to co-founding ITI, Dr. Mates was a co-founder of Functional Genetics, and served as its Chairman and Chief Executive Officer from December 2000 until August 2003. From 1989-1998 Dr. Mates was the President and a board member of North American Vaccine Inc. and its predecessor companies. She has served on several boards, and recently completed a board membership and a two-year chairmanship of the Board of the New York Biotechnology Association. Dr. Mates has also served on the Advisory Council of the Center for Society and Health at the Harvard School of Public Health, the Board of Visitors of the Biotechnology Institute of the University of Maryland and the board of directors of Gilda's Club of New York. Earlier in her career, Dr. Mates spent several years as a research analyst and investment banker, and as an advisor to the life sciences industry. Dr. Mates received her B.S. from the Ohio State University and her Ph.D. from the University of Washington, and completed her postdoctoral fellowships at The Massachusetts General Hospital and Harvard Medical School.

Dr. Alafi has served on the board of directors of ITI since January 2013. Dr. Alafi has been a General Partner of Alafi Capital Company, LLC, a venture capital firm, since 1995. He was previously a Physiology and Anatomy teacher at Santa Monica College, a visiting scholar in the Department of Chemistry at Stanford University and a researcher at DNAX. Dr. Alafi currently serves as a director of ISTO Technologies, Inc. and has previously served as a director of Coley Pharmaceutical Group, Inc., CyberGold, Inc. and Stereotaxis, Inc. Dr. Alafi received a B.A. in Biology from Pomona College and a D.Phil. in Biochemistry from the University of Oxford.

Recent Stock Transactions by Christopher Alafi Ph.D.
Date Type Shares Traded Price Range
Dec 30, 2016 Acquisition (Non Open Market) 960 n/a
Dec 7, 2016 Buy 20,826 16.14
Dec 6, 2016 Buy 44,174 16.33
Nov 14, 2016 Buy 34,000 14.50
Sep 30, 2016 Acquisition (Non Open Market) 951 n/a
Jun 30, 2016 Acquisition (Non Open Market) 373 n/a
Mar 31, 2016 Acquisition (Non Open Market) 377 n/a
Feb 29, 2016 Buy 100,000 29.70
Dec 31, 2015 Acquisition (Non Open Market) 195 53.79
Sep 30, 2015 Acquisition (Non Open Market) 262 n/a
Jun 30, 2015 Acquisition (Non Open Market) 328 n/a
Mar 31, 2015 Acquisition (Non Open Market) 439 n/a
Mar 11, 2015 Buy 625,000 24.00
Dec 31, 2014 Acquisition (Non Open Market) 594 n/a
Dec 1, 2014 Buy 1,422 14.75
Nov 28, 2014 Buy 35,000 14.75
Nov 19, 2014 Buy 1,034 14.25
Nov 18, 2014 Buy 3,531 14.23
Nov 14, 2014 Buy 133 15.07
Nov 13, 2014 Buy 2,200 15.12
Nov 12, 2014 Buy 5,000 15.23
Nov 11, 2014 Buy 5,000 15.55
Sep 30, 2014 Acquisition (Non Open Market) 765 n/a
Jun 30, 2014 Acquisition (Non Open Market) 1,245 n/a
Aug 29, 2013 Statement of Ownership 0 n/a

Dr. Lerner has served on the board of directors of ITI since 2002. Dr. Lerner served as President of the Scripps Research Institute, a private, non-profit biomedical research organization from 1986 to January 2012, and since then has served and continues to serve as Institute Professor. Dr. Lerner received the Wolf Prize in Chemistry in 1994, the California Scientist of the Year Award in 1996, the Paul Ehrlich and Ludwig Darmstaedter Prize in 2003, and the Prince of Asturias Award in 2012 for his achievements in the development of catalytic antibodies and combinatorial antibody libraries. Dr. Lerner is a member of the National Academy of Sciences and the Royal Swedish Academy of Sciences. Dr. Lerner served as a director of Kraft Foods, Inc. from 2005 to March 2012 and currently serves as a director of Opko Health, Inc., Teva Pharmaceutical Industries Ltd., and Sequenom, Inc. Dr. Lerner received his M.D. from Stanford Medical School.

Recent Stock Transactions by Richard Lerner M.D.
Date Type Shares Traded Price Range
Dec 30, 2016 Acquisition (Non Open Market) 911 n/a
Sep 30, 2016 Acquisition (Non Open Market) 902 n/a
Jun 30, 2016 Acquisition (Non Open Market) 354 n/a
Mar 31, 2016 Acquisition (Non Open Market) 364 n/a
Feb 18, 2016 Option Execute 10,000 1.36
Dec 31, 2015 Acquisition (Non Open Market) 188 53.79
Sep 30, 2015 Acquisition (Non Open Market) 252 n/a
Jun 30, 2015 Acquisition (Non Open Market) 316 n/a
Mar 31, 2015 Acquisition (Non Open Market) 423 n/a
Dec 31, 2014 Acquisition (Non Open Market) 508 n/a
Sep 30, 2014 Acquisition (Non Open Market) 601 n/a
Jun 30, 2014 Acquisition (Non Open Market) 978 n/a
Aug 29, 2013 Statement of Ownership 0 n/a

Mr. Marcus has served on the board of directors of ITI since April 2006. Mr. Marcus co-founded Alexandria Real Estate Equities, Inc. in 1994, Alexandria Venture Investments in 1996, and the annual Alexandria Summit in 2011. He has served as Chairman of the Board of Directors of Alexandria Real Estate Equities, Inc. since May 2007, Chief Executive Officer since March 1997, President since February 2009, and a director since the company's inception in 1994. From 1986 to 1994, Mr. Marcus was a partner at the law firm of Brobeck, Phleger & Harrison LLP, specializing in corporate finance and capital markets, venture capital, and mergers and acquisitions. From 1984 to 1994, he also served as General Counsel and Secretary of Kirin-Amgen, Inc., a joint venture that financed the development of, and owned patents to, two multi-billion dollar genetically engineered biopharmaceutical products. Mr. Marcus was formerly a practicing certified public accountant and tax manager with Arthur Young & Co. specializing in the financing and taxation of REITs. He received his undergraduate and Juris Doctor degrees from the University of California, Los Angeles. In addition to ITI, Mr. Marcus serves on the boards of the Accelerator Corporation, of which he was one of the original architects and co-founders, Foundation for the National Institutes of Health (FNIH), Multiple Myeloma Research Foundation (MMRF), and the Partnership for New York City. Mr. Marcus also served on the Board of Trustees of PennyMac Mortgage Investment Trust, a publicly traded mortgage REIT, from August 2009 to August 2012. Mr. Marcus received the Ernst & Young 1999 Entrepreneur of the Year Award (Los Angeles—Real Estate).

Recent Stock Transactions by Joel S. Marcus J.D., CPA.
Date Type Shares Traded Price Range
Jan 30, 2017 Disposition (Non Open Market) 95,000 n/a
Jan 30, 2017 Acquisition (Non Open Market) 95,000 n/a
Jan 26, 2017 Option Execute 95,000 1.50 - 3.26
Dec 30, 2016 Acquisition (Non Open Market) 994 n/a
Sep 30, 2016 Acquisition (Non Open Market) 984 n/a
Jun 30, 2016 Acquisition (Non Open Market) 386 n/a
Mar 31, 2016 Acquisition (Non Open Market) 386 n/a
Dec 31, 2015 Acquisition (Non Open Market) 199 53.79
Dec 8, 2015 Sell 22,700 54.80
Dec 7, 2015 Sell 40,000 52.15 - 53.78
Dec 4, 2015 Sell 30,000 55.96
Sep 30, 2015 Acquisition (Non Open Market) 268 n/a
Jun 30, 2015 Acquisition (Non Open Market) 336 n/a
Mar 31, 2015 Acquisition (Non Open Market) 450 n/a
Mar 31, 2015 Option Execute 15,000 0.96 - 1.36
Dec 31, 2014 Acquisition (Non Open Market) 609 n/a
Sep 30, 2014 Acquisition (Non Open Market) 784 n/a
Jun 30, 2014 Acquisition (Non Open Market) 1,275 n/a
Sep 9, 2013 Statement of Ownership 0 n/a

Mr. Riggs has served on our board of directors since January 2014. Mr. Riggs co-founded Royalty Pharma, an investment company focused on drug royalties, in 1996 and has served as Chairman of its investment committee since July 2003. Since April 2010, Mr. Riggs has served as founder and Chief Executive Officer of Syntax Analytics, LLC, a development stage venture focused on creating a new information technology platform for large-scale portfolio management. Since June 2006, Mr. Riggs has also served as Managing Member of New Ventures, a venture fund focused on healthcare. Since January 2001, Mr. Riggs has served as Managing Member of Balfour LLC, an investment management company focused on healthcare, biotechnology and technology. From 1996 until 2000, Mr. Riggs served as President and as a director of Biomatrix, Inc., a publicly-traded biopharmaceutical company. From 1991 to 1995, Mr. Riggs served as President and Chief Executive Officer of RF&P Corporation, an investment company owned by the State of Virginia Retirement System. Prior to that, he served as a managing director in PaineWebber's mergers and acquisitions department from 1981 to 1990. In addition to Royalty Pharma, Mr. Riggs serves on the board of directors of FibroGen, Inc. (since September 1993), a private biotechnology company; Cibus, LLC (since November 2001), a private agricultural technology company; GeneNews (since January 1998), a publicly-traded molecular diagnostic company; and eReceivables (since September 2003), a private healthcare service technology company. Mr. Riggs graduated from Middlebury College and holds an MBA from Columbia University.

Recent Stock Transactions by Rory B. Riggs
Date Type Shares Traded Price Range
Dec 30, 2016 Acquisition (Non Open Market) 960 n/a
Sep 30, 2016 Acquisition (Non Open Market) 951 n/a
Jun 30, 2016 Acquisition (Non Open Market) 373 n/a
Mar 31, 2016 Acquisition (Non Open Market) 382 n/a
Dec 31, 2015 Acquisition (Non Open Market) 197 53.79
Sep 30, 2015 Acquisition (Non Open Market) 265 n/a
Jun 30, 2015 Acquisition (Non Open Market) 332 n/a
Mar 31, 2015 Acquisition (Non Open Market) 444 n/a
Dec 31, 2014 Acquisition (Non Open Market) 601 n/a
Sep 30, 2014 Acquisition (Non Open Market) 774 n/a
Jun 30, 2014 Acquisition (Non Open Market) 1,260 n/a
Feb 5, 2014 Buy 28,571 17.50
Jan 8, 2014 Statement of Ownership 0 n/a
Jan 8, 2014 Statement of Ownership 0 n/a

Mr. Van Nostrand has served on our board of directors since January 2014. Mr. Van Nostrand was Executive Vice President and Chief Financial Officer of Aureon Biosciences, Inc., a private pathology life science company, from January 2010 to July 2010. Prior to joining Aureon Biosciences, Mr. Van Nostrand served as Executive Vice President and Chief Financial Officer of AGI Dermatics, Inc., a private biotechnology company, from July 2007 to September 2008 when the company was acquired. From May 2005 to July 2007, Mr. Van Nostrand served as the Senior Vice President and Chief Compliance Officer of OSI Pharmaceuticals, Inc., a publicly-traded biotechnology company, where he previously served as Vice President and Chief Financial Officer from December 1996 through May 2005 and as Vice President, Finance and Administration prior to that. He also served as OSI's Treasurer from March 1992 to May 2005 and Secretary from March 1995 to January 2004. Mr. Van Nostrand joined OSI as Controller and Chief Accounting Officer in September 1986. Prior to joining OSI, Mr. Van Nostrand served in a managerial position with the accounting firm, Touche Ross & Co., currently Deloitte. Mr. Van Nostrand serves as chairman of the board of directors of Metabolix, Inc., a publicly-traded biotechnology company, as well as chairman of its audit committee. Mr. Van Nostrand also serves on the board of directors of Achillion Pharmaceuticals, Inc., a publicly-traded biotechnology company, where he serves as chairman of the audit committee. He also serves on the board of directors of the Biomedical Research Alliance of New York, a private company providing clinical trial services. Mr. Van Nostrand was the former chairman of, and serves on, the board of the New York Biotechnology Association and serves on the Foundation Board of Farmingdale University. Previously, Mr. Van Nostrand served on the board of directors of Apex Bioventures, Inc., a special purpose acquisition company focused on life sciences. Mr. Van Nostrand holds a B.S. in Accounting from Long Island University, New York. He is a Certified Public Accountant.

Stock transaction information provided by EDGAR Online. Intra-Cellular Therapies Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.